Human Intestinal Absorption,-,0.7212,
Caco-2,-,0.8767,
Blood Brain Barrier,-,0.7750,
Human oral bioavailability,-,0.6429,
Subcellular localzation,Mitochondria,0.4619,
OATP2B1 inhibitior,-,0.5764,
OATP1B1 inhibitior,+,0.9193,
OATP1B3 inhibitior,+,0.9423,
MATE1 inhibitior,-,0.8200,
OCT2 inhibitior,-,0.8000,
BSEP inhibitior,-,0.6256,
P-glycoprotein inhibitior,+,0.6048,
P-glycoprotein substrate,+,0.7729,
CYP3A4 substrate,+,0.6404,
CYP2C9 substrate,-,1.0000,
CYP2D6 substrate,-,0.8232,
CYP3A4 inhibition,-,0.9400,
CYP2C9 inhibition,-,0.8847,
CYP2C19 inhibition,-,0.8476,
CYP2D6 inhibition,-,0.9096,
CYP1A2 inhibition,-,0.8691,
CYP2C8 inhibition,-,0.7957,
CYP inhibitory promiscuity,-,0.9899,
UGT catelyzed,-,0.0000,
Carcinogenicity (binary),-,0.9100,
Carcinogenicity (trinary),Non-required,0.5947,
Eye corrosion,-,0.9874,
Eye irritation,-,0.9465,
Skin irritation,-,0.7350,
Skin corrosion,-,0.9124,
Ames mutagenesis,-,0.6200,
Human Ether-a-go-go-Related Gene inhibition,-,0.5158,
Micronuclear,+,0.7300,
Hepatotoxicity,+,0.6534,
skin sensitisation,-,0.8536,
Respiratory toxicity,+,0.8000,
Reproductive toxicity,+,0.8778,
Mitochondrial toxicity,+,0.7625,
Nephrotoxicity,-,0.9183,
Acute Oral Toxicity (c),III,0.6341,
Estrogen receptor binding,+,0.6820,
Androgen receptor binding,+,0.6198,
Thyroid receptor binding,+,0.5629,
Glucocorticoid receptor binding,+,0.5611,
Aromatase binding,+,0.5390,
PPAR gamma,+,0.5723,
Honey bee toxicity,-,0.8577,
Biodegradation,-,0.6250,
Crustacea aquatic toxicity,-,0.7600,
Fish aquatic toxicity,-,0.5324,
Water solubility,-2.383,logS,
Plasma protein binding,-0.036,100%,
Acute Oral Toxicity,2.188,log(1/(mol/kg)),
Tetrahymena pyriformis,0.179,pIGC50 (ug/L),
